The company stands 4th in terms of total funding among its competitors. Vedanta Biosciences has raised $366M. As of February 28, 2026, the company has 97 employees. The latest funding round was a Series E round on February 23, 2024, led by Colorcon, with participation from AXA Investment Managers, AMR Action Fund, Gates Foundation, K2 HealthVentures, PureTech Health, Skyviews Life Science and Pfizer.
Cyborg Score Rationale
Well-capitalized clinical-stage biotech with $350M+ raised across 13 rounds, led by respected pharma and impact investors including Gates Foundation and Pfizer. Advanced pipeline with multiple Phase I/II programs in high-unmet-need areas (C. difficile, IBD, cancer immunotherapy). Yet pre-revenue status and competitive microbiome therapeutics market present execution risks.
Top Insights
Proprietary consortia technology: The company specializes in creating defined consortia of bacteria as therapeutic agents, utilizing the natural gut ecosystem to regulate and potentiate the immune system.
Phase 3 program advancing: VE303 for preventing recurrent Clostridioides difficile infection is in a Phase 3 trial that began in May 2024 with expected completion in October 2027.
Strategic manufacturing partnerships: Partnerships with Foxconn, Innolux, and Colorcon Ventures as of 2026-07-04 indicate strong interest in expanding manufacturing capabilities for bacterial therapies.
Prestigious investor syndicate: Investors include CARB-X, Seventure Partners, Pfizer, Bill & Melinda Gates Foundation, and Skyviews Life Science.
Named Competitors
VE303 / Microbiome Therapeutics — Microbiome-derived therapies for C. difficile infection and hematologic malignancies
Monoclonal Microbials / Oral Biologics — Single-strain microbes for immune, metabolic, and neurological therapeutic modulation
Infectious Disease Therapeutics — Small-molecule and biologic therapies for serious infections including resistant pathogens
Recent Developments
(February 2024) Completed Series E funding round led by Colorcon with participation from AXA IM Alts, AMR Action Fund, Gates Foundation, and Pfizer
(April 2024) Received $3.9M grant funding from CARB-X
(May 2024) Initiated Phase 3 clinical trial for VE303 in prevention of recurrent C. difficile infection
Open the full interactive Vedanta Biosciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.